Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Revolution Medicines (RVMD) Shares Outstanding (Weighted Average): 2018-2024

Historic Shares Outstanding (Weighted Average) for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to $168.2 million.

  • Revolution Medicines' Shares Outstanding (Weighted Average) rose 11.91% to $186.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.9 million, marking a year-over-year increase of 11.91%. This contributed to the annual value of $168.2 million for FY2024, which is 53.53% up from last year.
  • Latest data reveals that Revolution Medicines reported Shares Outstanding (Weighted Average) of $168.2 million as of FY2024, which was up 53.53% from $109.6 million recorded in FY2023.
  • In the past 5 years, Revolution Medicines' Shares Outstanding (Weighted Average) ranged from a high of $168.2 million in FY2024 and a low of $66.4 million during FY2020.
  • In the last 3 years, Revolution Medicines' Shares Outstanding (Weighted Average) had a median value of $109.6 million in 2023 and averaged $122.2 million.
  • Data for Revolution Medicines' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 53.53% (in 2024) over the last 5 years.
  • Over the past 5 years, Revolution Medicines' Shares Outstanding (Weighted Average) (Yearly) stood at $66.4 million in 2020, then rose by 11.01% to $73.7 million in 2021, then climbed by 20.50% to $88.8 million in 2022, then increased by 23.40% to $109.6 million in 2023, then skyrocketed by 53.53% to $168.2 million in 2024.